NasdaqGM:SUPN
NasdaqGM:SUPNPharmaceuticals

How Investors May Respond To Supernus Pharmaceuticals (SUPN) Raising 2025 Outlook After Sage Acquisition and Q2 Results

Supernus Pharmaceuticals recently reported its second-quarter 2025 earnings, showing year-over-year revenue of US$165.45 million and net income of US$22.5 million, alongside updated full-year guidance reflecting anticipated revenue of US$670 million to US$700 million due to strong first-half results and the Sage acquisition. While quarterly revenue declined slightly from the prior year, improved profitability and the upward revision in annual guidance highlight a significant shift in...
NasdaqGS:ACLX
NasdaqGS:ACLXBiotechs

Do Higher Losses at Arcellx (ACLX) Reflect a Strategic Shift or Growing Pains?

Arcellx, Inc. recently reported its second quarter 2025 earnings, disclosing a net loss of US$52.77 million, up from US$27.2 million in the same period last year, and a basic loss per share of US$0.94 versus US$0.51 year-over-year. This sharp increase in net loss highlights considerable changes in the company's cost structure or spending priorities compared to previous periods. We'll examine how Arcellx's significantly higher net losses this quarter influence its investment narrative and...
NasdaqGS:GTM
NasdaqGS:GTMInteractive Media and Services

ZoomInfo (GTM) Is Up 6.2% After Profit Return and Raised Revenue Guidance - What's Changed

ZoomInfo Technologies recently reported improved second quarter results with US$306.7 million in sales, returning to profitability and raising full-year revenue guidance to a range of US$1.215–1.225 billion, up from prior expectations. Along with completing a major share repurchase and appointing Michael Graham O’Brien as Chief Financial Officer, these developments highlight management’s confidence and a focus on operational discipline. We'll explore how the upgraded revenue outlook and...
NYSE:UE
NYSE:UERetail REITs

Does Urban Edge's $250 Million Equity Raise Signal a New Growth Phase for UE?

Urban Edge Properties recently completed a follow-on equity offering totaling US$250 million and filed a shelf registration to enable the issuance of additional securities, including common and preferred shares as well as debt instruments. This move greatly enhances the company’s financial flexibility, equipping it with fresh capital for future acquisitions, development projects, or potential debt reduction initiatives. We'll examine how the expanded capital base from the equity offering...
NYSE:CRL
NYSE:CRLLife Sciences

Are Margin Pressures Shaping Charles River’s (CRL) Competitive Position Amid Stabilizing Revenue Guidance?

Charles River Laboratories International recently announced its second quarter 2025 results, reporting revenue of US$1.03 billion and net income of US$52.33 million, both nearly flat or lower compared to the previous year, and updated its full-year outlook to reflect a smaller projected revenue decline. The company’s revised guidance, showing a softer fall in revenue and confirmation of earnings estimates, may indicate some stabilization in business conditions despite ongoing margin...